T
Talia Flanagan
Researcher at AstraZeneca
Publications - 49
Citations - 1326
Talia Flanagan is an academic researcher from AstraZeneca. The author has contributed to research in topics: Solubility & Dissolution testing. The author has an hindex of 15, co-authored 45 publications receiving 910 citations. Previous affiliations of Talia Flanagan include UCB.
Papers
More filters
Journal ArticleDOI
In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects
Erik Sjögren,Bertil Abrahamsson,Patrick Augustijns,Dieter Becker,Michael B. Bolger,Marcus E. Brewster,Joachim Brouwers,Talia Flanagan,Matthew D Harwood,Christian Heinen,René Holm,Hans-Paul Juretschke,Marlies Kubbinga,Anders Lindahl,Viera Lukacova,Uwe Münster,Sibylle Neuhoff,Mai Anh Nguyen,Achiel Van Peer,Christos Reppas,Amin Rostami Hodjegan,Christer Tannergren,Werner Weitschies,Clive G. Wilson,P. Zane,Hans Lennernäs,Peter Langguth +26 more
TL;DR: This review summarizes the current knowledge on anatomy and physiology of the human gastrointestinal tract in comparison with that of common laboratory animals with emphasis on in vivo methods for testing and prediction of oral dosage form performance.
Journal ArticleDOI
Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.
Fang Liu,Sejal R. Ranmal,Hannah Batchelor,Mine Orlu-Gul,Terry B. Ernest,Iwan W. Thomas,Talia Flanagan,Catherine Tuleu +7 more
TL;DR: A better understanding of the acceptability of existing formulations highlights opportunities for the development of new and more acceptable medicines and facilitates safe and effective prescribing for the young and older populations.
Journal ArticleDOI
Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review
Cordula Stillhart,Katarina Vučićević,Patrick Augustijns,Abdul Basit,Hannah Batchelor,Talia Flanagan,Ina Gesquiere,Rick Greupink,Daniel Keszthelyi,Mikko Koskinen,Christine M. Madla,Christophe Matthys,Goran Miljuš,Miriam G. Mooij,Miriam G. Mooij,Neil Parrott,Anna Lena Ungell,Saskia N. de Wildt,Saskia N. de Wildt,Mine Orlu,Sandra Klein,Anette Müllertz +21 more
TL;DR: This review provides an overview of GI tract properties in special populations compared to healthy adults and discusses how drug absorption is affected by these conditions.
Journal ArticleDOI
Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets
TL;DR: In silico absorption modeling has been performed, to assess the impact of in vitro dissolution on in vivo performance for ZURAMPIC (lesinurad) tablets, and indicated that drug product batches that pass the proposed dissolution specification of Q = 80% in 30 min are anticipated to be bioequivalent to the clinical reference batch.
Journal ArticleDOI
Biopharmaceutical aspects and implications of excipient variability in drug product performance.
TL;DR: This review aims to present current knowledge on excipient critical material attributes and their link to biopharmaceutical behavior and dissolution characteristics and attempts to describe the impact of physiological conditions on excipients functionality are addressed.